"Efficacy of tocilizumab in treatment of COVID-19 pneumonia: A case-control study from a tertiary care hospital".
作者信息
Barthwal M S, Ramesh C B Ashwin, Sahasrabudhe Tushar, Dole Sachinkumar
机构信息
Department of Respiratory Medicine, Dr. D.Y. Patil Medical College, Hospital and Research Centre, Pimpri, Pune, Maharashtra, India.
出版信息
Lung India. 2023 May-Jun;40(3):299-300. doi: 10.4103/lungindia.lungindia_540_22.
Abstract
摘要
相似文献
1
"Efficacy of tocilizumab in treatment of COVID-19 pneumonia: A case-control study from a tertiary care hospital".
Lung India. 2023 May-Jun;40(3):299-300. doi: 10.4103/lungindia.lungindia_540_22.
2
Adjuvant Tocilizumab in the Treatment of Patients with Moderate to Severe COVID-19 Pneumonia: An Observational Study.
J Assoc Physicians India. 2022 Jan;70(1):11-12.
3
Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital.
Infect Dis (Lond). 2021 Apr;53(4):291-302. doi: 10.1080/23744235.2021.1884286. Epub 2021 Feb 23.
4
A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Trials. 2020 Jun 3;21(1):470. doi: 10.1186/s13063-020-04447-3.
5
Efficacy of tocilizumab in treatment of COVID-19 pneumonia: A case-control study from a tertiary care hospital.
Lung India. 2022 Nov-Dec;39(6):510-516. doi: 10.4103/lungindia.lungindia_349_22.
6
Tocilizumab in patients with severe COVID-19: a retrospective cohort study.
Lancet Rheumatol. 2020 Aug;2(8):e474-e484. doi: 10.1016/S2665-9913(20)30173-9. Epub 2020 Jun 24.
7
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.
JAMA Intern Med. 2021 Jan 1;181(1):24-31. doi: 10.1001/jamainternmed.2020.6615.
8
Tocilizumab and steroid treatment in patients with COVID-19 pneumonia.
PLoS One. 2020 Aug 20;15(8):e0237831. doi: 10.1371/journal.pone.0237831. eCollection 2020.
9
Tocilizumab in the treatment of critical COVID-19 pneumonia: A retrospective cohort study of mechanically ventilated patients.
Int J Infect Dis. 2021 Feb;103:536-539. doi: 10.1016/j.ijid.2020.12.021. Epub 2020 Dec 14.
10
Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia.
Med Clin (Engl Ed). 2022 Apr 8;158(7):301-307. doi: 10.1016/j.medcle.2021.03.036. Epub 2022 May 3.
本文引用的文献
1
Efficacy of tocilizumab in treatment of COVID-19 pneumonia: A case-control study from a tertiary care hospital.
Lung India. 2022 Nov-Dec;39(6):510-516. doi: 10.4103/lungindia.lungindia_349_22.
2
Treatment with Tocilizumab in Adult Patients with Moderate to Critical COVID-19 Pneumonia: A Single-Center Retrospective Study.
Int J Infect Dis. 2022 Apr;117:1-7. doi: 10.1016/j.ijid.2022.01.048. Epub 2022 Jan 27.
3
Changes in Inflammatory Markers after Administration of Tocilizumab in COVID-19: A Single-Center Retrospective Study.
J Clin Med. 2021 Dec 25;11(1):107. doi: 10.3390/jcm11010107.
4
Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India.
BMC Infect Dis. 2021 Mar 5;21(1):241. doi: 10.1186/s12879-021-05912-3.
5
Tocilizumab in patients with severe COVID-19: a retrospective cohort study.
Lancet Rheumatol. 2020 Aug;2(8):e474-e484. doi: 10.1016/S2665-9913(20)30173-9. Epub 2020 Jun 24.
6
Association of inflammatory markers with the severity of COVID-19: A meta-analysis.
Int J Infect Dis. 2020 Jul;96:467-474. doi: 10.1016/j.ijid.2020.05.055. Epub 2020 May 18.
7
COVID-19: consider cytokine storm syndromes and immunosuppression.
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
Zotero 插件